probenecid + vicadrostat

**probenecid + vicadrostat** is a combination of two pharmacological agents: probenecid, a classic uricosuric agent that inhibits the renal tubular reabsorption of urate, and vicadrostat (BI 690517), an orally available, highly selective aldosterone synthase inhibitor. Probenecid increases urinary excretion of uric acid and is mainly used in gout and hyperuricemia, while also acting as a renal tubular blocking agent affecting the pharmacokinetics of various drugs. Vicadrostat selectively inhibits aldosterone synthase (CYP11B2), thereby reducing aldosterone production, with the aim of slowing the progression of chronic kidney disease (CKD) by impacting markers such as urine albumin-to-creatinine ratio. Both agents are small molecules. The combination has a pharmacological rationale for use in diseases with cardio-renal implications, particularly CKD, by targeting urate handling and mineralocorticoid pathway activity. As a combination, its clinical use is experimental and not yet established in routine practice[2][3][4][7].